Rapport Therapeutics (RAPP), which is backed by Johnson & Johnson’s (JNJ) venture capital arm, has filed to raise around $100M through an initial public offering.
The Boston-based biotech company didn’t specify any terms in its SEC filing, but indicated in the filing fee schedule that it was seeking around $100M, a number that is likely a placeholder and subject to change.
Rapport hopes to list its shares on Nasdaq under the symbol RAPP. Joint book runners include Goldman Sachs, Jefferies, TD Cowen and Stifel.
The company was founded in 2022, with support from Third Rock Ventures and J&J Innovation-JJDC. Arch Ventures and J&J Innovation-JJDC were cited in the filing as holding equity stakes of at least 5%.
Rapport has been working on treatments for central nervous system disorders. Its lead drug is RAP-219, which is entering Phase 2a testing for the treatment of focal epilepsy.